2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024
Open accessThe DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index; 152 of the 254 sources its claims cite were checked for support.
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
CoChat Summary
TL;DR
This ADA Standards of Care chapter provides updated recommendations for diagnosing and classifying diabetes, prediabetes, and related forms, including diagnostic thresholds, screening intervals, and classification categories. It emphasizes confirmatory testing, A1C limitations, risk-based screening, and special populations such as type 1 diabetes, gestational diabetes mellitus (GDM), cystic fibrosis–related diabetes (CFRD), posttransplantation diabetes mellitus (PTDM), pancreatic diabetes, and monogenic diabetes.
Key findings
- Diabetes diagnostic criteria: A1C ≥6.5% (≥48 mmol/mol), FPG ≥126 mg/dL (≥7.0 mmol/L), 2-h PG ≥200 mg/dL (≥11.1 mmol/L) during 75-g OGTT, or random plasma glucose ≥200 mg/dL (≥11.1 mmol/L) with classic hyperglycemic symptoms/crisis; absent unequivocal hyperglycemia, diagnosis requires two abnormal results. Prediabetes is defined by A1C 5.7–6.4% (39–47 mmol/mol), FPG 100–125 mg/dL (5.6–6.9 mmol/L; IFG), or 2-h PG 140–199 mg/dL (7.8–11.0 mmol/L; IGT).
- Classification includes type 1 diabetes (5–10% of diabetes), type 2 diabetes (90–95%), specific types due to other causes, and GDM. Misdiagnosis is common and can occur in ~40% of adults with new type 1 diabetes; type 1 diabetes staging shows ~44% 5-year risk of symptomatic disease at stage 1 and ~60% risk by 2 years and ~75% within 5 years at stage 2.
- Screening: begin at age 35 years for all adults; consider earlier in adults with overweight/obesity plus one or more risk factors; repeat at minimum 3-year intervals if normal. In children/adolescents, consider risk-based screening after puberty or age 10 years, whichever is earlier, with overweight/obesity plus risk factors.
- Special populations: GDM screening at 24–28 weeks; one-step IADPSG criteria increase GDM diagnosis (e.g., 11.5% vs 4.9% in a 2021 USPSTF review) without demonstrated improved health outcomes. CFRD occurs in about 20% of adolescents and 40–50% of adults with cystic fibrosis; annual OGTT screening begins by age 10, and A1C is not recommended for screening due to low sensitivity. PTDM diagnosis is best made once stable on immunosuppression, usually at least 45 days after transplantation, with OGTT preferred. Monogenic diabetes accounts for <5% of diabetes; 80–85% of neonatal diabetes cases have a monogenic cause, and 30–50% of KATP-related neonatal diabetes improves with high-dose oral sulfonylureas.
Methods
- Design: ADA Standards of Care clinical practice guideline/consensus recommendations, updated annually by the ADA Professional Practice Committee, an interprofessional expert committee.
- Data/sample: No primary study sample; the chapter synthesizes published evidence and expert consensus. It references an ADA evidence-grading system (A/B/C/E) detailed in the Introduction and Methodology.
- Main analysis: Narrative synthesis of diagnostic, classification, and screening evidence with graded recommendations; no meta-analysis or primary data collection is reported in this chapter.
Limitations
- Stated evidence gaps include insufficient evidence for continuous glucose monitoring (CGM) for screening/diagnosis of prediabetes or diabetes; unknown optimal screening interval; uncertain benefit of treating early abnormal glucose metabolism; lack of randomized controlled trials for treating versus not treating GDM diagnosed by IADPSG but not Carpenter-Coustan criteria; and limited data on how treating maternal hyperglycemia affects offspring metabolic outcomes.
- Stated classification/diagnostic limitations include common misdiagnosis (e.g., ~40% of adults with new type 1 diabetes), poorly understood type 2 diabetes genetics, inadequate genetic data in diverse populations, and A1C unreliability in conditions such as hemoglobin variants, pregnancy, glucose-6-phosphate dehydrogenase deficiency, HIV, hemodialysis, recent blood loss/transfusion, or erythropoietin therapy.
- Evident from the text: this is a consensus guideline rather than a primary systematic review or meta-analysis; recommendations are graded A/B/C/E, with some based on expert consensus (E), and many cited studies are observational/cohort rather than randomized trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 2.1 Flowchart for investigation of suspected type 1 diabetes in newly diagnosed adults, based on data from White European populations. 1 No single clinical feature con fi rms type 1 diabetes in isolation. 2 Glutamic acid decarboxylase (GAD) should be the primary antibody measured and, if negative, should be followed by islet tyrosine phosphatase 2 (IA-2) and/or zinc transporter 8 (ZnT8) where these tests are available. In individuals who have not been treated with insulin, antibodies against insulin may also be useful. In those diagnosed at < 35 years of age who have no clinical features of type 2 diabetes or monogenic diabetes, a negative result does not change the diagnosis of type 1 diabetes, since 5 -10% of people with type 1 diabetes do not have antibodies. 3 Monogenic diabetes is suggested by the presence of one or more of the following features: A1C < 58 mmol/mol ( < 7.5%) at diagnosis, one parent with diabetes, features of a speci fi c monogenic cause (e.g., renal cysts, partial lipodystrophy, maternally inherited deafness, and severe insulin resistance in the absence of obesity), and monogenic diabetes prediction model probability > 5% (diabetesgenes.org/exeter-diabetes-app/ModyCalculator). 4 A C-peptide test is only indicated in people receiving insulin treatment. A random sample (with concurrent glucose) within 5 h of eating can replace a formal C-peptide stimulation test in the context of classi fi cation. If the result is $ 600 pmol/L ( $ 1.8 ng/mL), the circumstances of testing do not matter. If the result is < 600 pmol/L ( < 1.8 ng/mL) and the concurrent glucose is < 4 mmol/L ( < 70 mg/dL) or the person may have been fasting, consider repeating the test. Results showing very low levels (e.g., < 80 pmol/L [ < 0.24 ng/mL]) do not need to be repeated. Where a person is insulin treated, C-peptide must be measured prior to insulin discontinuation to exclude severe insulin de fi ciency. Do not test C-peptide within 2 weeks of a hyperglycemic emergency. 5 Features of type 2 diabetes include increased BMI ( $ 25 kg/m 2 ), absence of weight loss, absence of ketoacidosis, and less marked hyperglycemia. Less discriminatory features include non-White ethnicity, family history, longer duration and milder severity of symptoms prior to presentation, features of the metabolic syndrome, and absence of a family history of autoimmunity. 6 If genetic testing does not con fi rm monogenic diabetes, the classi fi cation is unclear and a clinical decision should be made about treatment. 7 Type 2 diabetes should be strongly considered in older individuals. In some cases, investigation for pancreatic or other types of diabetes may be appropriate. 8 A person with possible type 1 diabetes who is not treated with insulin will require careful monitoring and education so that insulin can be rapidly initiated in the event of glycemic deterioration. 9 C-peptide values 200 -600 pmol/L (0.6 -1.8 ng/mL) are usually consistent with type 1 diabetes or maturity-onset diabetes of the young but may occur in insulin-treated type 2 diabetes, particularly in people with normal or low BMI or after long duration. Reprinted and adapted from Holt et al. (36).](https://figures.cochat.ai/paper-figures/7be96ed282694b1c85997763e16ae474/2-diagnosis-and-classification-of-diabetes-i-standards-of-care-in-diabetes2024-i-figure-1.png)

Verification
Claims the paper makes
99 Valid · 9 Not valid · 35 Not checked · 32 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However , in 2003 the ADA adopted the new range of 100 -125 mg/dL (5.6 -6.9 mmol/L) to better de fi ne IFG so that the population risk of developing diabetes with IFG would be similar to that with IGT (11).”
What the sources say
- Disputedcites [11] Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 2003, Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care sourceExperimental — accuracy not yet measured
In “The new criteria” (p. 8), the committee defines IFG as fasting plasma glucose of 110 to <126 mg/dL, not 100–125 mg/dL. The paper describes both IFG and IGT as risk factors for future diabetes, but it does not say the lower IFG threshold was adopted to make their population risks similar. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In most cases, such stressor steroidinduced hyperglycemia resolves by the time of discharge (142,143).”
What the sources say
- Partly supportedcites [142] Thomas, 2000, Early peri-operative hyperglycaemia and renal allograft rejection in patients without diabetes, BMC Nephrol sourceExperimental — accuracy not yet measured
The Results (Hyperglycaemia; page unavailable) show that mean glucose fell from immediately after surgery to the morning of day 2. The Discussion (page unavailable) describes steroid exposure and postoperative hyperglycaemia, but the paper does not report whether most patients’ hyperglycaemia resolved by discharge. (LLM, conf=0.82)
- Disputedcites [143] Chakkera, 2009, Hyperglycemia during the immediate period after kidney transplantation, Clin J Am Soc Nephrol sourceExperimental — accuracy not yet measured
The Abstract (Results) says hyperglycemia was sustained throughout hospitalization and that 66% of patients without pretransplantation diabetes required insulin at discharge. The Discussion says the authors did not know what proportion would ultimately recover, rather than finding that most cases resolved by discharge. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Because periodontal disease is associated with diabetes, the utility of screening in a dental setting and referral to primary care as a means to improve the diagnosis of prediabetes and diabetes has been explored (108 -110)”
What the sources say
- Not checked — no full text of the sourcecites [108] Lalla, 2013, Dental findings and identification of undiagnosed hyperglycemia, J Dent Res source
- Not checked — no full text of the sourcecites [109] Lalla, 2011, Identification of unrecognized diabetes and pre-diabetes in a dental setting, J Dent Res source
- Supportedcites [110] Herman, 2015, Screening for prediabetes and type 2 diabetes in dental offices, J Public Health Dent source
The Discussion (page unavailable) describes periodontal disease and its sequelae as risk factors for dysglycemia, supporting the general association claimed. The paper’s own Results (page unavailable) found no association between clinical evidence of periodontitis and dysglycemia in its study sample, so it should not be cited as demonstrating that association in this cohort. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a community-based study of African American and non-Hispanic White adults without diabetes, baseline A1C was a stronger predictor of subsequent diabetes and cardiovascular events than fasting glucose (82).”
What the sources say
- Partly supportedcites [82] Selvin, 2010, Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults, N Engl J Med sourceExperimental — accuracy not yet measured
The Abstract Conclusions state that glycated hemoglobin was more strongly associated than fasting glucose with cardiovascular disease risk, but only similarly associated with diabetes risk. The study population was community-based and included Black and White adults without diabetes. Page numbers are not provided in our copy. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The epidemiologic studies that formed the basis for recommending A1C to diagnose diabetes included only adult populations (112).”
What the sources say
- Could not verifycites [112] Cowie, 2010, Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006, Diabetes Care sourceExperimental — accuracy not yet measured
The introductory discussion (page unavailable) says an international expert committee recommended A1C for diagnosis, but does not give the ages of participants in the epidemiologic studies behind that recommendation. The Research Design and Methods section (page unavailable) includes participants aged 12 and older in this paper’s own analysis; that does not establish the ages in the studies the committee relied on. Searches for adult-only evidence and pediatric populations did not resolve the claim. (LLM, conf=0.73)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
74 more claims · 46 with their cited sources checked
Create a free account to see all 175 claims and to verify the 3 references still open.
- Probably not a substantial claim. 29
- It may state two separate claims as one. 75
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HbA1c can be affected by some non-glycaemic factors, including anaemia due to iron deficiency or malaria, specific haemoglobin variants (eg, HbS and HbF), other haemoglobinopathies, polycythaemia due to living in high altitude, liver and kidney diseases, HIV, and specific drugs such as antiretroviral therapy for HIV.”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many clinical guidelines recommend using a second confirmatory test for diabetes diagnosis and initiating treatment,6,21–23 although there is variation in this guidance.”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [21]
Experimental — accuracy not yet measured
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.023 · Cited by 7,283
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s081 · Cited by 5,974
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes
The International Expert Committee (2009) · Diabetes Care · doi:10.2337/dc09-9033 · Cited by 3,185
Research works printed but not linked: 1
- International Diabetes Federation . IDF Diabetes Atlas, 10th edition. Brussels, Belgium, International Diabetes Federation, 2021. Accessed 26 September 2023. Available from https://www.diabetesatlas.org/atlas/tenth-edition/
Cited by
Items 1,401–1,500 of 2,029
Qin, R., Jiang, C., Zhang, M., Hou, X., Tao, X., Pan, S., & Wang, Z. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109216
Zeng, L., Bai, J., Zou, X., Zheng, Y., Liu, G., Lin, R., Zhao, Y. X., Xue, X., & Wang, X. (2025) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-025-06221-3 · Cited by 3
“DM diagnosis adhered to the criteria of the American Diabetes Association Professional Practice Committee [27].”
Maximiano‐Barreto, M. A., Pereira, J. A. D. S., & Bastos‐Silva, V. J. (2025) · Research Square · doi:10.21203/rs.3.rs-6905019/v1
Zhu, B., Wu, P., He, Z., Ma, J., Yan, N., Ma, Y. F., Yan, R., Ma, T., Ma, R., Cong, G., et al. (2025) · Journal of Human Hypertension · doi:10.1038/s41371-025-01090-w · Cited by 2
“The identi fi cation of diabetes mellitus [16] was based on either the self-reported use of antidiabetic medications or elevated blood glucose readings, characterized by casual blood glucose levels of 11.1 mmol/L or higher, fasting blood glucose levels of 7.0 mmol/L or higher, or 2-hour postprandial…”
InfluentialLv, Q., & Wang, Z. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2585662
“…based on one or more of the following criteria: (1) a physician-diagnosed case of diabetes; (2) use of insulin or oral hypoglycemic agents; (3) a two-hour oral glucose tolerance test (OGtt) result ≥ 11.1 mmol/l, or fasting blood glucose ≥ 7.0 mmol/l; (4) glycated hemoglobin (Hba1c) ≥ 6.5% [16].”
InfluentialFajardo-Espinoza, F. S., Becerra-Herrera, R., Cabello-Díaz, D. C., Cruz‐Ramos, M., Cabrera-Nieto, S. A., Pérez-Camargo, D. A., Barranco-Cortés, A., Ceballos, Á. J. D., Bargalló‐Rocha, E., & Torres-Domínguez, J. A. (2025) · Nutrición Hospitalaria · doi:10.20960/nh.05701
“However, other tests such as glycosylated hemoglobin, oral glucose tolerance test or repeat fasting plasma glucose are needed to confirm the diagnosis (18).”
Szeląg, K., Opalińska, A., Lubas, C., Folta, P., Kłosowska, J., Błądzińska, K., Błądziński, M., Zach, M., Świerczek, P., & Kujawski, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3892
Heterogeneity in paediatric diabetes clinical presentation and its link to disease severityPreprint
Garzón, M. A. J., Muganga, S. I., Tallapragada, D. S. P., et al. (2025) · medRxiv · doi:10.1101/2025.11.10.25339758
Sadiq, M. A., Ibrahim, S. M., & Mansur, M. E. (2025) · The Open Public Health Journal · doi:10.2174/0118749445431057251106054749
Hou, H., Zha, X., Lu, Z., Chen, P., Wang, L., Wang, F., & Wang, R. (2025) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-025-08483-2
“Factors contributing to its increasing incidence include rising obesity rates, maternal age, and changes in diagnostic criteria [2].”
Diabetes in Children: Nutritional Considerations
Narasimhan, S., & Hyland, J. (2025) · Springer eBooks · doi:10.1007/978-3-031-97759-6_36
Shi, L., Zhang, S., Cai, L., et al. (2025) · Journal of Medical Biochemistry · doi:10.5937/jomb0-62295
The regulatory effects of realgar and cinnabar on glucose metabolism in mice
Zhang, Y., Qu, Q., Dai, E., Liu, R., Jin, B., Lu, Z., Kong, H., Zhang, Y., Qu, H., & Zhao, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1658148
Mawatari, S., Tanoue, S., Kumagai, K., Oda, K., Toyodome, A., Sakae, H., Fujisaki, K., Inada, Y., Uto, H., Saisyoji, A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-29972-6
“DM was defined as treatment with antidiabetic medications, fasting blood glucose level ≥ 126 mg/dL, 2-h plasma glucose level ≥ 200 mg/dL during a 75-g oral glucose tolerance test, and/or hemoglobin A1c concentration ≥ 6.5% on a single test or on two or more separate occasions 28 .”
InfluentialFang, D., Yu, X., Zhang, P., Feng, W., Hong, T., & Gu, T. (2025) · Nutrition & Metabolism · doi:10.1186/s12986-025-01041-9
Gestational Diabetes mellitus: The evolution of diagnostic criteria
Holtz, B. M., Paula, V. G., Gomes, M. E. P., Volpato, G. T., & Damasceno, D. C. (2025) · Research Society and Development · doi:10.33448/rsd-v14i11.50245
Safitri, A. H., Sayyida, R. A., Widayati, E., & Tyagita, N. (2025) · Tropical Journal of Natural Product Research · doi:10.26538/tjnpr/v9i11.16
Magny‐Normilus, C., Jeon, S., Schnipper, J. L., Wu, B., & Whittemore, R. (2025) · Diabetology · doi:10.3390/diabetology6120154
“Measuring HbA 1c is the common test for assessing glycemic control and is a key criterion for diabetes diagnosis [5,14,15].”
Yang, X., Liu, L., Wang, X., & Zhou, S. (2025) · BMC Public Health · doi:10.1186/s12889-025-25840-0
“The following questions were employed to identify participants with diabetes [17]: “Are you currently taking insulin?””
Research Progress on Intervention for Type 2 Diabetes by Activating Endogenous GLP-1 Secretion
管, 佩. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15123455
Evaluation of the Glucose-Regulating Function of a Momordica charantia Compound Capsule
Wu, T., Lee, M., Hsu, Y.-J., Huang, C., Wang, J., & Chien, Y.-J. (2025) · Universal library of medical and health sciences. · doi:10.70315/uloap.ulmhs.2025.0304004
Cissé, A. H., Kuang, A., Allard, C., Ronkainen, J., Beaumont, R. N., Sebert, S., Scholtens, D. M., Hattersley, A. T., Vääräsmäki, M., Kajantie, E., et al. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005382
“GDM diagnosis is characterized by a lower fasting plasma glucose threshold than type 2 diabetes (5.1 mmol/L vs 7.0 mmol/L), 21 reflecting the importance of maternal fasting glycemia on risk of adverse pregnancy outcomes.”
InfluentialA leap forward in early vascular aging research: uncovering the high-risk vascular aging patterns
Martínez‐Rodrigo, A., Saz‐Lara, A., Pedrosa, J., Otero-Luis, I., Moreno-Herráiz, N., Lever‐Megina, C. G., Martínez-Ortega, I. A., Pastor, J. M., & Cavero‐Redondo, I. (2025) · International Journal of Data Science and Analytics · doi:10.1007/s41060-025-00976-9
“Regarding HbA1c, our HRVA group threshold of 5.93% falls near the upper pre-diabetic range, consistent with the literature [39], while the 5.39% threshold for the HVA group reflects a level within the normal range.”
InfluentialRenal manifestations and diabetes mellitus: the missing link
Akpalu, J., Boima, V., & Abobi-Kanbigs, D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33090-2.00009-6
Association of ABO Blood Groups with Osteoporotic Hip Fracture Susceptibility in Chinese Adults
Qi, R., Wang, B., Tian, F., Liu, Q., Chu, L., Cao, A., Tang, T., & Zhang, M. (2025) · Calcified Tissue International · doi:10.1007/s00223-025-01461-y
Gurgoglione, F. L., Donelli, D., Frazzetto, M., et al. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15120594
“DM status was defined by a known clinical history of type 2 DM or diagnosis based on American Diabetes Association diagnostic criteria [30].”
Zinc-Related Proteasome Variants in Type 1 Diabetes: An in Silico-Guided Case-Control Study
Nasre‐Nasser, R. G., Vieira, A. C. M., Pellenz, F. M., Moretto, L., Girardi, E., Assmann, T. S., Lu, C., Canani, L. H. S., Dieter, C., & Crispim, D. (2025) · Metabolites · doi:10.3390/metabo15120772
“T1DM diagnosis was confirmed based on the criteria established by the American Diabetes Association [19].”
Oshakbayev, K., Durmanova, A., Bikhanov, N., Nabiyev, A., Suleimenov, T., Idrisov, A., Daniyarova, G., Kurgambekova, D., Sagimbayeva, M., & Kuttymuratov, G. (2025) · Research Square · doi:10.21203/rs.3.rs-8096250/v1
Wang, P., Kumar, K., Lambertini, L., Liu, H., Wood, O., Chen, S., Pillard, A., Scott, D. K., Paulo, J. A., Gygi, S. P., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.07.692818
Andrade, L. J. D. O., de Oliveira, G. C. M., Bittencourt, A. M. V., Salles, O. J. D. M., & de Oliveira, L. M. (2025) · Research Square · doi:10.21203/rs.3.rs-8302280/v1
Chivoret, E., Perroud, N. A., Pataky, Z., et al. (2025) · Patient Education and Counseling · doi:10.1016/j.pec.2025.109448
Subclinical renal injury in obesity following bariatric surgery: insights from a prospective cohort
Yang, P., Yang, W., Lee, P., Chen, C., Lin, M.-T., & Wu, V. (2025) · Surgical Endoscopy · doi:10.1007/s00464-025-12464-z
Kamieniak, A., & Gieroba, D. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3884
Longitudinal assessment of pancreatic exocrine dysfunction in type 1 diabetes
Bolado, F., Zabalza, L., Artajo, J. D. C., et al. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i12.112799
Thuong, P.-T., Ha, T. K. Q., Nguyen, D.-T., Tuan, V. V., Ponce-Zea, J.-E., Doan, T., Mai, V.-H., & Oh, W. K. (2025) · Phytochemistry · doi:10.1016/j.phytochem.2025.114751 · Cited by 1
Takei, S., Hamada, K., Shimizu, N., Sakurai, M., Nojiri, T., & Yahagi, N. (2025) · medRxiv · doi:10.64898/2025.12.14.25342210
Emmanuel, N. S., Ibrahim, M., Yusuf, L., Mustapha, R. B., Moyinoluwa, L. O., Abdulrahman, Y. E., Anuh, H. I., Usman, Y., Yaduma, W. G., Eze, E. D., et al. (2025) · The Journal of Basic and Applied Zoology · doi:10.1186/s41936-025-00532-8 · Cited by 2
Thakur, G., Han, J.-H., Jo, C.-H., Oh, S.-J., Kim, T.-S., Hong, C., Lee, S., Kumar, R., Kang, Y., & Rho, G. (2025) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5c00979
Liu, F., Wang, W., Pan, H.-W., Jin, H., You, Y., & Liu, Z. (2025) · Archives of Public Health · doi:10.1186/s13690-025-01778-y · Cited by 1
“3 ) physician-diagnosed diabetes [27].”
Enhancing Early Detection of Diabetes Mellitus Type 2 using Machine Learning and Class Balancing
Gumay, A. E., Pratama, G. A. D. R. P., Jufonda, J., & Yulistiani, R. (2025) · Proceeding of the Electrical Engineering Computer Science and Informatics · doi:10.1109/eecsi67060.2025.11290470
“The significant frequency is particularly alarming, as numerous patients stay undetected until difficulties arise, thus highlighting the challenge and necessity for early identification techniques that might alleviate the public health issue and enhance long-term outcomes in many populations [3][4].”
Trends and factors associated with diabetes screening, diagnosis and treatment in Peru, 2014-2024Preprint
Guzman‐Vilca, W. C., Curisinche-Rojas, M., Solis, G., & Timaná-Ruíz, R. (2025) · medRxiv · doi:10.64898/2025.12.18.25342639 · Cited by 1
Pereira, L. B., Schroeder, H. T., dos Santos, J. K., Capelari, P. C. B., Schaan, B. D., & Bock, P. M. (2024) · Figshare · doi:10.6084/m9.figshare.27019439
Pereira, L. B., Schroeder, H. T., dos Santos, J. K., Capelari, P. C. B., Schaan, B. D., & Bock, P. M. (2024) · Figshare · doi:10.6084/m9.figshare.27019445
Zhao, S., wang, Z., Qing, P., Li, M., Liu, Q., Pang, X., Wang, K., Gao, X., Zhao, J., & Wu, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26299266
Campos, M. A., Oppermann, M. L. R., Sanseverino, M. T. V., GUERRA, G. L., Hirakata, V. N., & Reichelt, A. J. (2024) · Figshare · doi:10.6084/m9.figshare.26748032
Szydełko, J., Czop, M., Petniak, A., Lenart-Lipińska, M., Kocki, J., Zapolski, T., & Matyjaszek‐Matuszek, B. (2024) · Figshare · doi:10.6084/m9.figshare.26755663
Chen, H. L., Wu, C., Cao, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26231149
Pereira, L. B., Schroeder, H. T., dos Santos, J. K., Capelari, P. C. B., Schaan, B. D., & Bock, P. M. (2024) · Figshare · doi:10.6084/m9.figshare.27019442
Chang, J., Zhou, Z., Hong, W., Li, S., & Zhu, Z. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100395 · Cited by 3
“According to the Standards of Medical Care in Diabetes-2024, published by the American Diabetes Association (ADA), the FPG level of ≥ 7.0 mmol/L is considered one of the key diagnostic criteria of diabetes mellitus [18].”
InfluentialМАРКЕРИ МЕТАБОЛІЧНИХ ПОРУШЕНЬ ЗАЛЕЖНО ВІД ФЕНОТИПУ ОЖИРІННЯ
Sekret, T. V., Vlasenko, M. V., & Stepaniuk, A. (2025) · Терапевтика · doi:10.31793/2709-7404.2025.1-6.49
Kumar, S., Kumar, Mukesh, Priyanka, Kumar, A., & Singh, A. (2025) · International Journal of Science and Healthcare Research · doi:10.52403/ijshr.20250412
The Role of Prognostic Nutritional Index in UTI Susceptibility Among Female Type 2 Diabetic Patients
Lu, C., Liu, Q., Feng, P., Liu, H.-Y., Shan, Y.-M., & Chen, M. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/6890754
Bashir, S., Ishaq, G. M., Mushtaq, I., Ganie, M. A., Wani, I., Alanazi, M., Asiri, I., Hussain, A., Khan, K. U., & Anwar, S. (2025) · Diseases · doi:10.3390/diseases13120405 · Cited by 1
“Renal function was evaluated by serum urea, serum creatinine, estimated glomerular filtration rate (eGFR, calculated using the CKD-EPI equation [16]), and CKD staging.”
Houri, O., Romano, A., Walfisch, A., Hadar, E., Gilboa, Y., Perl, L., Loebl, N., & Unger, R. (2025) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.70751
“33”
The Hidden Cost of Metformin: Deficiency of Vitamin B12 in Iraqi Patients with Type 2 Diabetes
Obaid, N. M., Salih, H. T., Hussein, M. A., Amin, Y. M. I. A.-M., & Oglah, M. R. (2025) · Maaen Journal for Medical Sciences · doi:10.55810/2789-9136.1086
Guerrero-Flores, M. H., Maeda-Gutiérrez, V., Galvan-Tejada, C. E., Galván-Tejada, J. I., Cruz, M., Flores-Chaires, L. A., Vazquez, K. T., Magallanes‐Quintanar, R., & Saldívar-Pérez, J. (2025) · Diagnostics · doi:10.3390/diagnostics16010053 · Cited by 1
“Traditional diagnostic markers such as fasting plasma glucose, the oral glucose tolerance test (OGTT), and HbA1c remain the clinical standard for the diagnosis of type 2 diabetes [6,7].”
Systems Bioinformatics Applied to Elucidating the Progression from Prediabetes to Type 2 DiabetesPreprint
Andrade, L. J. D. O., de Oliveira, G. C. M., Bittencourt, A. M. V., Salles, O. J. D. M., & de Oliveira, L. M. (2025) · Research Square · doi:10.21203/rs.3.rs-8420018/v1
Morar-Stan, A., Dobrotă, L., Radutu, A., & Domnariu, C. D. (2025) · medRxiv · doi:10.64898/2025.12.19.25342708
Type 2 Diabetes and Iron Deficiency: The Effect of Oral and Intravenous Iron Therapy on HbA1c
Timurkaan, E. S., Timurkaan, M., & Uslu, M. F. (2025) · Hippocrates Medical Journal · doi:10.58961/hmj.1833166
Dholariya, S. J., Singh, G., Kaliya, M., Singh, R., Sonagra, A. D., & Parchwani, D. N. (2025) · Biomarkers in Medicine · doi:10.1080/17520363.2025.2608945
Mortazavizadeh, S. M. R., Rafatmagham, S., & Rahimi, M. (2025) · Journal of Translational Medical Research · doi:10.61882/jbums.32.3.237
Chen, L. N. (2025) · Clinical and Experimental Obstetrics & Gynecology · doi:10.31083/ceog42782 · Cited by 1
Naseeb, M., Albajri, E. A., Hakim, N. A. N., Almasaudi, A. S., Afeef, S., Basaqr, R., Naghi, S. N., & Mosli, H. H. (2025) · International Journal for Vitamin and Nutrition Research · doi:10.31083/ijvnr45398
Velasco-Muñoz, V., Silva-Ortiz, S., Rodríguez-Fula, N., & Palencia-Sánchez, F. (2025) · Salud Trabajo y Sostenibilidad (Consejo Colombiano de Seguridad) · doi:10.63434/30286999.148
Whelan, J., & Kole‐White, M. B. (2025) · Contemporary surgical clerkships · doi:10.1007/978-3-031-96541-8_19
Bieniaszewski, K., Szymański, M., Wilczyński, M., et al. (2026) · Obesity Surgery · doi:10.1007/s11695-025-08458-4
Evaluation of Sexual Functions in Individuals with Type 2 Diabetes
Topçu, K., & Bektaş, H. (2025) · Hacettepe Üniversitesi Sağlık Bilimleri Fakültesi Dergisi · doi:10.21020/husbfd.1673243
Zhi, Y., Xue, G., wang, Y., et al. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109453
Qin, R., Hou, X., Jiang, C., et al. (2026) · BMC Medical Imaging · doi:10.1186/s12880-025-02146-6
“DM was defined as meeting at least one of the following criteria: fasting blood glucose ≥ 7.0 mmol/L, glycated hemoglobin A1c ≥ 6.5%, 2-hour oral glucose tolerance test blood glucose ≥ 11.1 mmol/L, current use of hypoglycemic agents [17].”
InfluentialCajavilca, M. F., Finik, J., Ðoàn, L. N., Pagán, J. A., Wu, B., Fletcher, J., & Sadarangani, T. R. (2026) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-025-02839-2
Kim, D., Kim, J., Im, M., Ryang, S., Kim, M., Kim, Y. J., Kim, I. J., Kim, Y. K., Kang, H., Chung, S. T., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1726006
Wang, X. H., Wang, S., Liu, X., Xie, R., Liang, S., Wang, B., & Zhang, Y. Q. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1674287
“Conventional prognostic models have predominantly utilized isolated parameters including natriuretic peptide levels, glycated hemoglobin A1c (HbA1c), and New York Heart Association (NYHA) functional classification (5, 6).”
From metabolism to myocardium: the missing link of admission dysglycemia in early cardiac recovery
Khan, F. R., Akbar, F. E., & Aslam, K. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00265-1
Huang, W., Jie, H., Yi, J., Liu, Q., Li, S., Luo, Y., Tang, S., Chi, Z., & Wu, C. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1640882 · Cited by 1
“The diagnosis of T2DM was based on criteria established by the World Health Organization (WHO) or the American Diabetes Association (ADA) (23, 24).”
Wagner, J. A., Akyirem, S., Lipson, J., Chen, H. N., & Whittemore, R. (2026) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1689830
“As previously reported, all participants received standard T2D care at their CHC (25).”
Sahoo, D. R., Babu, S. K., Sahu, A., et al. (2026) · Chemistry & Biodiversity · doi:10.1002/cbdv.202503022
The effect of antidepressant medication use on HbA1c levels in type 2 diabetes
Sağlam, F., Nas, N., & Sağlık, S. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1693817 · Cited by 1
“The diagnosis of T2D in the study participants was established based on the diagnostic criteria outlined by the American Diabetes Association (ADA) (15).”
Effects of Japan tallow on gut microbiota in type 2 diabetic mice
Xie, K., Zhang, Y., Yu, L. J. Z., Yu, X., He, J., & Su, Y. (2026) · Nutrition & Metabolism · doi:10.1186/s12986-026-01079-3
“As a prevalent chronic metabolic disorder, T2DM is principally defined by impaired pancreatic β-cell function and peripheral insulin resistance, culminating in relative insulin deficiency [1].”
Wang, S.-Y., Liu, X. Y., Li, Z.-M., Deng, C.-X., Chen, K., Zhuang, S.-Y., Xu, B., & Xu, T. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i1.114535
Szydełko, J., Zapolski, T., Lenart-Lipińska, M., Czop, M., Petniak, A., Kocki, J., & Matyjaszek‐Matuszek, B. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-025-03055-2 · Cited by 1
“Briefly, the diagnosis of T2DM was established according to the American Diabetes Association guidelines [26].”
Chang, Y.-P., Chen, Y., Lee, J., et al. (2026) · Journal of Medical Virology · doi:10.1002/jmv.70797
“…as a known diagnosis or treatment for T2D, or by two abnormal test results (HbA1c ≥ 6.5% and fasting glucose ≥ 126 mg/dL); prediabetes as HbA1c levels of 5.7%–6.4% or fasting glucose levels of 100–125 mg/dL; and normoglycemia as HbA1c levels < 5.7% and fasting glucose levels < 100 mg/dL [31].”
InfluentialSun, S., Gong, S., Ba, T., Li, M., Liu, W., zhang, R., Ma, Y., Wang, F., Cai, X., Luo, Y., et al. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101729
Li, Z., Guan, X.-C., Li, X., Chen, Y.-Y., Ruan, F., & Long, L. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05518-0
“The diagnosis of T2DM was established on the basis of American Diabetes Association criteria or ongoing hypo-glycaemic therapy (oral agents or insulin) [17].”
Taormina, V. M., Eisenhardt, S., Gilbert, M. P., Kien, C. L., Poynter, M. E., & Kraft, J. (2026) · Lipidology · doi:10.3390/lipidology3010004
“…that participants (i) were 45–75 years of age, (ii) had a body mass index of 20–45 kg/m 2 , (iii) had a fasting blood glucose concentration of 100–125 mg/dL or a hemoglobin A1C of 5.7–6.4% (i.e., had prediabetes [30]), and (iv) were free of other chronic diseases apt to affect inflammatory tone.”
InfluentialType 1 diabetes: early diagnosis and treatment prospects
Alimova, I. (2025) · Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) · doi:10.21508/1027-4065-2025-70-6-5-10
Preoperative Assessment and Optimization
Selzer, A. R., & Cloyd, B. H. (2026) · Springer eBooks · doi:10.1007/978-3-032-12007-6_2
Liu, Y., Chen, Y., Wang, L., Jiang, Z., & Gao, Z. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1719112
Wei, B., Gao, T., & Liu, Q. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1721267
IL-21 mediates crosstalk between T cells and NK cells during the remission of type 1 diabetes
Lei, K., Li, X., Zhong, T., Tang, R., Deng, Q., Love, P. E., Zhou, Z., Zhao, B., & Li, X. (2026) · Nature Metabolism · doi:10.1038/s42255-025-01439-y
Han, T. S., Khong, T. K., Selvanayagam, V. S., & Yusof, A. J. (2026) · International Journal of Sport Nutrition and Exercise Metabolism · doi:10.1123/ijsnem.2025-0158
Km, C., Ting, W., Lee, Y.-J., Huang, C.-Y., Lin, C., Huang, S.-K., Lee, Y.-C., Wang, L.-T., Kao, Y.-E., Wu, Y.-H., et al. (2026) · Pediatrics & Neonatology · doi:10.1016/j.pedneo.2025.10.010
Sui, X., Xiong, W., Fu, Q., Huang, J., Li, J., Xie, T., Xu, Y., Chen, J., Zhang, Y., & Chen, J. (2026) · Kidney Diseases · doi:10.1159/000550128
“The diagnostic criteria for these comorbidities are detailed in online supplementary Table 1 (for all online suppl. material, see https://doi.org/ 10.1159/000550128) [11].”
InfluentialOuchida, S., Saito, R., Ohama, N., Kuwamura, M., & Fukano, R. (2026) · Cureus · doi:10.7759/cureus.102039
Su, Y., Yang, Q. Z., Xing, C., Wang, H., Li, R., Zhang, J., Mei, J., & He, J. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/2596620
Лаптев, Д. Н., Титович, Е. В., Федоринин, А. А., Bezlepkina, O. B., Peterkova, V. A., Рамилевич, М. И., & Mokrysheva, N. G. (2026) · Diabetes Mellitus · doi:10.14341/dm13361
“Стадия 1 соответствует началу аутоиммунного про-цесса и повреждения бета-клеток поджелудочной желе-зы, хотя и не сопровождается нарушением метаболизма глюкозы (нормогликемия) [9–11].”
Huang, B., Zheng, M., Li, J., Fang, C., Wu, Y., Xiao, Y., Yu, P., Gu, W., Zhou, S., Zhang, Y., et al. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02067-y · Cited by 1
“The diagnosis of diabetes mellitus (DM) followed standardized criteria, including fasting plasma glucose levels ≥ 126 mg/dL (≥ 7.0 mmol/L), HbA1c levels > 6.5% [26], a prior DM diagnosis, or evidence of antidiabetic medication use, such as insulin or oral glucose-lowering agents.”
InfluentialChen, M., Zhou, X., Yang, K., Li, Q., Zhao, L., Wang, X., & Lu, Y. C. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1737669
“Although fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c) are well-established diagnostic standards for diabetes, they may be less sensitive to early or subclinical metabolic alterations (4).”
Ganesh, V. K., Pancharethinam, D., Sargurunathan, E. A. V., Mary, R. I. J., Appusamy, K., & Venkatesha, R. R. G. (2026) · Annals of African Medicine · doi:10.4103/aam.aam_557_25
“[1] The risk of developing type 2 diabetes increases with age, obesity, and lack of physical activity.”
Ji, M., Zeng, Z., Huang, Z., Shi, Z., & Ji, M. (2026) · Metabolites · doi:10.3390/metabo16020093 · Cited by 1
“Patients with T2D often have obesity and insulin resistance as comorbidities, and obesity is itself a significant independent risk factor for T2D [3].”
Metadata
- Authors
- American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., Khunti, K., Lingvay, I., Matfin, G., McCoy, R. G., Perry, M. L., Pilla, S. J., Polsky, S., Prahalad, P., Pratley, R. E., Segal, A. R., Seley, J. J., Selvin, E., Stanton, R. C., & Gabbay, R. A.
- ORCID
- ElSayed, Nuha A.
- Aleppo, Grazia
- Bannuru, Raveendhara R.
- Bruemmer, Dennis
- Collins, Billy S.
- Ekhlaspour, Laya
- Gaglia, Jason L.
- Hilliard, Marisa E.
- Johnson, Eric L.
- Khunti, Kamlesh
- Lingvay, Ildiko
- McCoy, Rozalina G.
- Perry, Mary Lou
- Pilla, Scott J.
- Polsky, Sarit
- Prahalad, Priya
- Pratley, Richard E.
- Segal, Alissa R.
- Seley, Jane Jeffrie
- Selvin, Elizabeth
- Stanton, Robert C.
- Gabbay, Robert A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2023-12-11
- Volume
- 47
- Issue
- Supplement_1
- Pages
- S20-S42
- ISSN
- 0149-5992 (ISSN-L)
- PMC
- PMC10725812
- OpenAlex
- W4389560718
- Cited by
- 2,086
- References
- 232
- Citations by year
- 2026: 771 · 2025: 903 · 2024: 408 · 2023: 1
- FWCI
- 74.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK121942)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- diabetes diagnosis, diabetes classification, diabetes mellitus, clinical guidelines, American Diabetes Association standards of care, quality of care
- MeSH terms
- Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.